In current clinical practice, third-generation CDK inhibitors (mainly including palbociclib, abemaciclib, and ribociclib) have received approval from the FDA for the treatment of HR + /HER2- advanced breast cancer. This evidence concerns the gene ERBB2 and breast cancer.